Join
Live feed
·
NEWSReleasevia Quantisnow
Moderna Inc. logo

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
MRNA· Moderna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRNA (Moderna Inc.) and more on Quantisnow.